Literature DB >> 22201974

Database documentation of retrotransposon insertion polymorphisms.

Ping Liang1, Wanxiangfu Tang.   

Abstract

Retrotransposons constitute more than 40 percent of the human genome with L1, Alu, SVA, and HERVs known to remain active in transposition. Retrotransposition contribute to genetic diversity in the form of retrotransposon insertion polymorphism (RIP) that is defined as the presence or absence of a retrotransposon insertion among human populations at a specific genomic location. So far close to 5000 cases of RIPs have been identified with more than 50 cases associated with disease. A large number of new RIPs are being and to be identified from newly available personal genomes data, making RIPs an important source of genetic variations/mutations that deserve proper documentation. In this review, we discuss the special characteristics of RIPs and the challenges in their compiling and annotating, and we examine the current status of database documentation of RIPs and describe in details the design, data schema, and utilities of dbRIP, which is currently the only database dedicated to the documentation of retrotransposon insertion polymorphism. Some future perspectives and outstanding issues associated with documentation of RIPs are also presented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22201974     DOI: 10.2741/479

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  3 in total

1.  Reference SVA insertion polymorphisms are associated with Parkinson's Disease progression and differential gene expression.

Authors:  Abigail L Pfaff; Vivien J Bubb; John P Quinn; Sulev Koks
Journal:  NPJ Parkinsons Dis       Date:  2021-05-25

Review 2.  Transposable elements and their potential role in complex lung disorder.

Authors:  Muralidharan Sargurupremraj; Matthias Wjst
Journal:  Respir Res       Date:  2013-10-05

Review 3.  Human Endogenous Retroviruses in Neurological Diseases.

Authors:  Patrick Küry; Avindra Nath; Alain Créange; Antonina Dolei; Patrice Marche; Julian Gold; Gavin Giovannoni; Hans-Peter Hartung; Hervé Perron
Journal:  Trends Mol Med       Date:  2018-03-15       Impact factor: 11.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.